Business Context and Reporting Period
Company: Atkore Inc. (ATKR)
Filing Type: Form 8-K (Current Report)
Date of Report: August 3, 2026
Event Date: August 2, 2026
Context: Atkore Inc. entered into a definitive Merger Agreement with Prysmian S.p.A. (Buyer) to be acquired in an all-cash transaction. The Company will survive the merger as a wholly-owned subsidiary of the Buyer.
Key Financial Metrics and Transaction Terms
- Merger Consideration: $95.00 per share in cash, without interest.
- Equity Award Treatment:
- Options: Canceled and converted to cash equal to the excess of the Merger Consideration over the exercise price.
- RSUs, PSUs, and DSUs: Canceled and converted to cash equal to the Merger Consideration multiplied by the number of underlying shares.
- Dividend Restriction: No dividends other than regular quarterly dividends of no greater than $0.33 per share per quarter.
- Termination Fee (Company): $115,920,000 payable to Buyer under specific conditions (e.g., superior proposal, change in recommendation).
- Financing: The transaction is not subject to a financing contingency; Buyer represented it has sufficient funds available.
Note: This filing does not provide standard operating financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes and Conditions
The primary material change is the execution of the Merger Agreement. The consummation of the transaction is subject to the following conditions:
- Stockholder Approval: Affirmative vote of holders of a majority of outstanding Company Stock.
- Regulatory Approvals: Expiration of waiting periods under the Hart-Scott-Rodino Act and receipt of clearance from governmental entities in Austria, Australia, and Canada.
- Legal Conditions: Absence of any law or order preventing the consummation of the Merger.
- Representations and Covenants: Accuracy of representations and performance of covenants by both parties.
- No Material Adverse Effect: Absence of a material adverse effect on the Company since the agreement date.
Guidance, Outlook, and Risks
Management Commentary: The Board of Directors has unanimously approved the agreement and recommends stockholder approval. The Company has agreed to a "non-solicit" provision but retains a "fiduciary out" to consider superior proposals under specific circumstances.
Timeline: The agreement may be terminated if the Effective Time has not occurred by August 3, 2027, subject to two automatic three-month extensions if closing conditions (excluding regulatory approvals) are met.
Risks and Contingencies:
- Failure to obtain stockholder or regulatory approval.
- Termination of the agreement due to breaches or superior proposals.
- Disruption of business operations, retention of key personnel, and customer relationships.
- Forward-looking statements regarding the transaction's benefits and timing are subject to uncertainties.
Investor Verification Checklist
- Verify the final vote count and outcome of the Company Stockholder Meeting.
- Monitor the status of regulatory approvals, specifically in Austria, Australia, and Canada.
- Review the definitive Proxy Statement for detailed financial projections and risk factors.
- Confirm the treatment of specific equity awards (options, RSUs, PSUs) based on individual grant terms.
- Watch for any announcements regarding superior competing proposals or changes in the Board's recommendation.